Kallubai et al., 2015 - Google Patents

Comparative binding mechanism of lupeol compounds with plasma proteins and its pharmacological importance

Kallubai et al., 2015

View PDF
Document ID
9042497133805818726
Author
Kallubai M
Rachamallu A
Yeggoni D
Subramanyam R
Publication year
Publication venue
Molecular BioSystems

External Links

Snippet

Lupeol, a triterpene, possesses beneficial effects like anti-inflammatory and anti-cancer properties. Binding of lupeol and its derivative (phytochemicals) to plasma proteins such as human serum albumin (HSA) and α-1-acid glycoprotein (AGP) is a major determinant in the …
Continue reading at pubs.rsc.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
Kallubai et al. Comparative binding mechanism of lupeol compounds with plasma proteins and its pharmacological importance
Noel et al. Triptolide and its derivatives as cancer therapies
Garg et al. Anticancer inhibitors of Hsp90 function: beyond the usual suspects
Chakraborti et al. Curcumin recognizes a unique binding site of tubulin
Patel et al. Inhibition of amyloid fibril formation of lysozyme by ascorbic acid and a probable mechanism of action
Yeggoni et al. Binding and molecular dynamics studies of 7-hydroxycoumarin derivatives with human serum albumin and its pharmacological importance
Gupta et al. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
Ben-Hail et al. Novel compounds targeting the mitochondrial protein VDAC1 inhibit apoptosis and protect against mitochondrial dysfunction
Dal Piaz et al. Drug affinity responsive target stability (DARTS) identifies laurifolioside as a new clathrin heavy chain modulator
Yeggoni et al. A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin: biophysical and computational approach
Yeggoni et al. Protein stability, conformational change and binding mechanism of human serum albumin upon binding of embelin and its role in disease control
Ardi et al. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins
Bodalia et al. Loss of endoplasmic reticulum Ca2+ homeostasis: contribution to neuronal cell death during cerebral ischemia
AU781272B2 (en) Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
Gokara et al. Differential interactions and structural stability of chitosan oligomers with human serum albumin and α-1-glycoprotein
Yu et al. Acylhydrazone derivatives as potential anticancer agents: Synthesis, bio-evaluation and mechanism of action
Wu et al. Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo
US7241804B1 (en) Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
Raghav et al. Berberine induces toxicity in HeLa cells through perturbation of microtubule polymerization by binding to tubulin at a unique site
Yeggoni et al. Elucidating the binding interaction of andrographolide with the plasma proteins: biophysical and computational approach
Xu et al. Probing the binding reaction of cytarabine to human serum albumin using multispectroscopic techniques with the aid of molecular docking
Mondal et al. Molecular interaction between human serum albumin (HSA) and phloroglucinol derivative that shows selective anti-proliferative potential
Ivasechko et al. Molecular design, synthesis and anticancer activity of new thiopyrano [2, 3-d] thiazoles based on 5-hydroxy-1, 4-naphthoquinone (juglone)
Yin et al. Supramolecular Encapsulation and Bioactivity Modulation of a Halonium Ion by Cucurbit [n] uril (n= 7, 8)
Dhar et al. Actin–curcumin interaction: Insights into the mechanism of actin polymerization inhibition